Compare Regeneron Pharmaceuticals Inc (REGN) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Invesco S&P 500 High Div Low Volatility ETF trades at $51.89. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Invesco S&P 500 High Div Low Volatility ETF nearer its low. Which is the better fit depends on your goals.
| REGN | SPHD | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | — |
52-Week High | $852.03 | $53.55 |
52-Week Low | $555.51 | $46.96 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
SPHD trades at $51.96, down 0.65% today, with mixed technical signals showing a bullish overall trend but bearish moving averages. The ETF focuses on high dividend yield and low volatility, offering monthly income payments of $0.21. Recent news highlights SPHD's 4.4% yield appeal amid market volatility, though some analysts question its total return potential compared to peers like SCHD.
The outlook remains balanced between income generation and growth limitations. SPHD provides stable monthly dividends attractive for conservative investors, but faces competition from higher-quality dividend ETFs. Key risks include exposure to yield traps and weaker drawdown recovery, requiring careful consideration of total return objectives versus income needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
